Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04662437
Other study ID # 08122020
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 10, 2020
Est. completion date December 9, 2020

Study information

Verified date December 2020
Source Bezmialem Vakif University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

COVID-19 infection causes a hypersensitive immune reaction and widespread inflammation in various organs of the body, especially through cytokines in the lungs. This cytokine-mediated widespread inflammation can also affect the parathyroid glands, resulting in impaired parathyroid secretion. Researchers evaluated the levels of parathyroid hormone, calcium, phosphorus, and alkaline phosphatase in patients hospitalized for COVID-19 infection. Researchers excluded patients on intensive care therapy and patients with known parathyroid disease. The researchers examined the association of parathyroid hormone secretion with COVID-19 disease, white blood cells, neutrophil / lymphocyte ratio, C reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone level of healthy people without COVID-19 infection and known parathyroid disease with the parathyroid hormone level of Covid-19 patients.


Description:

The coronavirus-2 (SARS-COV-2) virus, which can cause severe acute respiratory syndrome through the droplet, has caused the global Coronavirus 19 (COVID-19) pandemic. COVID-19 infection can be asymptomatic or lead to serious illness and even death. This virus causes a hypersensitive immune reaction and varying degrees of widespread inflammation through cytokines in various organs of the body, mainly the lungs. Cytokine-mediated widespread inflammation caused by the virus may also affect the parathyroid glands, causing their functions to deteriorate. Thus, it may cause changes in parathyroid hormone secretion. The researchers evaluated the results of serum parathyroid hormone, calcium, phosphorus, alkaline phosphatase tests in patients who were symptomatic and hospitalized with COVID-19 infection. Participants also evaluated the relationship of parathormone with white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone levels of patients with COVID-19 infection with the parathyroid hormone levels of healthy individuals without COVID-19 infection and parathyroid disease. So the investigators looked for differences in parathyroid hormone levels between both groups. Researchers did not include patients in the intensive care unit and patients with known parathyroid disease.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date December 9, 2020
Est. primary completion date December 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - To accept research. - Being over the age of 18. - COVID 19 test results to be positive. - Not taking parathyroid disease medication before. - Receiving inpatient treatment in the COVID service in the hospital. Exclusion Criteria: - Not accepting research. - Be under the age of 18. - Negative COVID 19 test results for patients. - COVID patients treated as outpatient. - Parathyroid disease in the healthy control group.

Study Design


Intervention

Diagnostic Test:
Venous blood was collected for biochemistry testing
From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.

Locations

Country Name City State
Turkey Bezmialem VU Istanbul

Sponsors (2)

Lead Sponsor Collaborator
Bezmialem Vakif University Didem Ertorul

Country where clinical trial is conducted

Turkey, 

References & Publications (3)

di Filippo L, Formenti AM, Doga M, Frara S, Rovere-Querini P, Bosi E, Carlucci M, Giustina A. Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients. Endocrine. 2020 Nov 9. doi: 10.1007/s12020-020-02541-9. [Epub ahead of print — View Citation

Somasundaram NP, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Dissanayake HA, Yogendranathan N, Gamage KKK, de Silva NL, Sumanatilleke M, Katulanda P, Grossman AB. The Impact of SARS-Cov-2 Virus Infection on the Endocrine System. J Endocr Soc. 2020 Jul 2; — View Citation

Sun JK, Zhang WH, Zou L, Liu Y, Li JJ, Kan XH, Dai L, Shi QK, Yuan ST, Yu WK, Xu HY, Gu W, Qi JW. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging (Albany NY). 2020 Jun 25;12(12):11287-11295. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of parathyroid hormone between groups In the study, serum parathyroid hormone results of the Covid patient group and non-Covid control groups were recorded and compared statistically. 90 days
Primary Comparison of calcium between groups In the study, serum calcium results of the Covid patient group and non-Covid control groups were recorded and compared statistically. 90 days
Primary Comparison of phosphorus between groups In the study, serum phosphorus results of the Covid patient group and non-Covid control groups were recorded and compared statistically. 90 days
Primary Comparison of alkaline phosphatase between groups In the study, serum alkaline phosphatase results of the Covid patient group and non-Covid control groups were recorded and compared statistically. 90 days
Primary White blood cells (WBC) results of Covid 19 patient group In the study, serum WBC results were recorded in Covid 19 patient groups. 90 days
Primary Neutrophil / lymphocyte ratio (N/LO) results of Covid 19 patient group In the study, serum N/LO results were recorded in Covid 19 patient groups. 90 days
Primary C-reactive protein (CRP) results of Covid 19 patient group In the study, serum CRP results were recorded in Covid 19 patient groups. 90 days
Primary Fibrinogen results of Covid 19 patient group In the study, serum fibrinogen results were recorded in Covid 19 patient groups. 90 days
Primary Procalcitonin results of Covid 19 patient group In the study, serum procalcitonin results were recorded in Covid 19 patient groups. 90 days
Primary Ferritin results of Covid 19 patient group In the study, serum ferritin results were recorded in Covid 19 patient groups. 90 days
Primary D-dimer results of Covid 19 patient group In the study, serum D-dimer results were recorded in Covid 19 patient groups. 90 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04997551 - Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19 Phase 3
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Completed NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Terminated NCT04455815 - A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) Phase 2
Recruiting NCT05792878 - Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
Completed NCT04659200 - Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
Recruiting NCT04470583 - Evaluating Clinical Parameters of COVID-19 in Pregnancy
Withdrawn NCT04377568 - Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Phase 2
Completed NCT04848610 - The Factors That Affect the Infection of COVID-19
Recruiting NCT04582903 - Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Recruiting NCT06032000 - Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203) Phase 1
Terminated NCT04941703 - "CHANGE COVID-19 Severity" Phase 1/Phase 2
Active, not recruiting NCT04639466 - A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection Phase 1/Phase 2
Completed NCT04575038 - CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 Phase 2
Recruiting NCT05022446 - The Impact of COVID-19 on Pulmonary Procedures
Completed NCT04347798 - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Active, not recruiting NCT04650178 - Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
Recruiting NCT04169542 - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
Recruiting NCT04382781 - Immunosupressive Treatment in COVID-19 Patients